Синдром ограниченной подвижности суставов при сахарном диабете

У больных сахарным диабетом (СД) часто встречаются изменения опорно-двигательного аппарата (ОДА), в частности хайроартропатия – специфическое поражение соединительнотканных структур кисти в условиях персистирующей гипергликемии, приводящее к ограничению подвижности суставов, как правило, в отсутствие болевого синдрома. Некоторые авторы для описания поражения ОДА при СД используют термин «синдром ограниченной подвижности суставов» (ОПС), поскольку при длительном течении в патологический процесс вовлекаются мелкие и крупные суставы не только верхней, но и нижней конечности. ОПС является одним из малоизученных и плохо диагностируемых состояний в сравнении с традиционными микрои макрососудистыми осложнениями СД, которым, ввиду прямой корреляции с продолжительностью жизни, уделяется большее внимание. Синдром ОПС ассоциирован с другими поздними осложнениями СД и может значимо нарушать функциональную активность, самообслуживание и ухудшать качество жизни. Считается, что повреждения околосуставных тканей и суставов при СД вызваны накоплением конечных продуктов гликирования. Решающую роль в диагностике хайроартропатии играет клинический осмотр.

1. Дедов ИИ, Шестакова МВ, Викулова ОК и др. Сахарный диабет в Российской Федерации: распространенность, заболеваемость, смертность, параметры углеводного обмена и структура сахароснижающей терапии по данным Федерального регистра сахарного диабета, статус 2017 г. Сахарный диабет. 2018;21(3):144-59. doi: 10.14341/DM9686 [Dedov II, Shestakova MV, Vikulova OK, et al. Diabetes mellitus in Russian Federation: prevalence, morbidity, mortality, parameters of glycaemic control and structure of hypoglycaemic therapy according to the Federal Diabetes Register, status 2017. Sakharnyi Diabet = Diabetes Mellitus. 2018;21(3):144-59. doi: 10.14341/DM9686 (In Russ.)].

2. Rosenbloom AL, Silverstein JH. Connective tissue and joint disease in diabetes mellitus. Endocrinol Metab Clin North Am. 1996;25:473-83. doi: 10.1016/S0889-8529(05)70335-2

3. Smith LL, Burnet SP, McNeil JD. Musculoskeletal manifestations of diabetes mellitus. Br J Sports Med. 2003;37:30-5. doi: 10.1136/bjsm.37.1.30

4. Pandey A, Usman K, Reddy H, et al. Prevalence of hand disorders in type 2 diabetes mellitus and its correlation with microvascular complications. Ann Med Health Sci Res. 2013;3:349-54. doi: 10.4103/2141-9248

5. Shinabarger NI. Limited joint mobility in adults with diabetes mellitus. Phys Ther. 1987;67:215-8. doi: 10.1093/ptj/67.2.215

6. Abate M, Schiavone C, Pelotti P, Salini V. Limited joint mobility in diabetes and ageing: recent advances in pathogenesis and therapy. Int J Immunopathol Pharmacol. 2010;23:997-1003. doi: 10.1177/039463201002300404

7. Lundbaek K. Stiff hands in long-term diabetes. Acta Med Scand 1957;158:447-51. doi: 10.1111/j.0954-6820.1957.tb15511.x

8. Rosenbloom AL, Frias JL. Diabetes mellitus, short stature and joint stiffness – a new syndrome. Clin Res. 1974;22:92A.

9. Jennings AM, Milner PC, Ward JD. Hand abnormalities are associated with the complications of diabetes in type 2 diabetes. Diabet Med. 1989;6:43-7. doi: 10.1111/j.1464-5491.1989.tb01137.x

10. Rosenbloom AL, Silverstein JH, Lezotte DC, et al. Limited joint mobility in childhood diabetes mellitus indicates increased risk for microvascular disease. N Engl J Med. 1981;305:191-4. doi: 10.1056/NEJM198107233050403

11. Jacobson AM, Braffett BH, Cleary PA, et al. The long-term effects of type 1 diabetes treatment and complications on health-related quality of life: a 23-year followup of the Diabetes Control and Complications/Epidemiology of Diabetes Interventions and Complications cohort. Diabetes Care. 2013;36:3131-8. doi: 10.2337/dc12-2109

12. Gamstedt A, Holm-Glad J, Ohlson CG, Sundstr?m M. Hand abnormalities are strongly associated with the duration of diabetes mellitus. J Intern Med. 1993;234:189-93. doi: 10.1111/j.1365-2796.1993.tb00729.x

13. Sukenik S, Weitzman S, Buskila D, et al. Limited joint mobility and other rheumatological manifestations in diabetic patients. Diabete Metab. 1987;13:187-92.

14. Pal B, Anderson J, Dick WC, Griffiths ID. Limitation of joint mobility and shoulder capsulitis in insulin- and non-insulindependent diabetes mellitus. Br J Rheumatol. 1986;25:147-51. doi: 10.1093/rheumatology/25.2.147

15. Arkkila PE, Kantola IM, Viikari JS. Limited joint mobility in noninsulin-dependent diabetic (NIDDM) patients: correlation to control of diabetes, atherosclerotic vascular disease, and other diabetic complications. J Diabet Complicat. 1994;11:208-17. doi: 10.1016/S1056-8727(96)00038-4

16. Starkman HS, Gleason RE, Rand LI, et al. Limited joint mobility (LJM) of the hand in patients with diabetes mellitus: relation to chronic complications. Ann Rheum Dis. 1986;45:130-5. doi: 10.1136/ard.45.2.130

17. Larkin ME, Barnie A, Braffett BH, et al. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group (2014) Musculoskeletal complications in type 1 diabetes. Diabetes Care. 2014;37:1863-9. doi: 10.2337/dc13-2361

18. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-86. doi: 10.1056/NEJM199309303291401

19. Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a longterm follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care. 1999;22:99-111. doi: 10.2337/diacare.22.1.99

20. Gokcen N, Altuntas SC, Benlidayi IC. An overlooked rheumatologic manifestation of diabetes: diabetic cheiroarthropathy. Clin Rheumatol. 2019;38:927-32. doi: 10.1007/s10067-019-04454-z

21. Fatemi A, Iraj B, Barzanian J, et al. Musculoskeletal manifestations in diabetic versus prediabetic patients. Int J Rheum Dis. 2015;18:791-9. doi: 10.1111/1756-185X.12712

22. Fujii K, Yamagishi T, Nagafuchi T, et al Biochemical properties of collagen from ligaments and periarticular tendons of the human knee. Knee Surg Sports Traumatol Arthrosc. 1994;2:229-33. doi: 10.1007/BF01845593

23. Saito M, Marumo K. Collagen cross-links as a determinant of bone quality: a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus. Osteoporos Int. 2010;21:195- 214. doi: 10.1007/s00198-009-1066-z

24. Vazzana N, Santilli F, Cuccurullo C, Davi G. Soluble forms of RAGE in internal medicine. Intern Emerg Med. 2009;4:389-401. doi: 10.1007/s11739-009-0300-1

25. Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products. Circulation. 2006;114(6):597-605. doi: 10.1161/circulationaha.106.621854

26. Abate M, Schiavone C, Di Carlo L, Salini V. Achilles tendon and plantar fascia in recently diagnosed type II diabetes: role of body mass index. Clin Rheumatol. 2012;31:1109-13. doi: 10.1007/s10067-012-1955-y

27. Franco R, Sanchez-Olea R, Reyes-Reyes EM, Panayiotidis MI. Environmental toxicity, oxidative stress and apoptosis: menage a trois. Mutat Res. 2009;674:3-22. doi: 10.1016/j.mrgentox.2008.11.012

28. Abate M, Schiavone C, Salini V. Neoangiogenesis is reduced in chronic tendinopathies of type 2 diabetic patients. Int J Immunopathol Pharmacol. 2012;25:757-61. doi: 10.1177/039463201202500322

29. Wang SH, Sun ZL, Guo YJ, et al. PPARgamma-mediated advanced glycation end products regulation of neural stem cells. Mol Cell Endocrinol. 2009;307:176-84. doi: 10.1016/j.mce.2009.02.012

30. Oliva F, Giai Via A, Maffulli N. Physiopathology of intratendinous calcific deposition. BMC Med. 2012;10:95. doi: 10.1186/1741-7015-10-95

31. Rui YF, Lui PP, Chan LS, et al. Does erroneous differentiation of tendon-derived stem cells contribute to the pathogenesis of calcifying tendinopathy? Chin Med J (Engl). 2011;124:606-10. doi: 10.3760/cma.j.issn.0366-6999.2011.04.022

32. Мокрышева НГ, Еремкина АК, Мирная СС и др. Патологические изменения в суставах и мышцах при первичном гиперпаратиреозе. Остеопороз и остеопатии. 2018;21(4):10-8. doi: 10.14341/osteo9783 [Mokrysheva NG, Eremkina AK, Mirnaya SS, et al. Joint and muscle involvement in primary hyperparathyroidism. Osteoporoz i Osteopatii = Osteoporosis and Bone Diseases. 2018;21(4):10-8. doi: 10.14341/osteo9783 (In Russ.)].

33. Conde J, Gomez R, Bianco G, et al. Expanding the adipokine network in cartilage: identification and regulation of novel factors in human and murine chondrocytes. Ann Rheum Dis. 2011;70:551- 9. doi: 10.1136/ard.2010.132399

34. Berry PA, Jones SW, Cicuttini FM, et al. Temporal relationship between serum adipokines, biomarkers of bone and cartilage turnover, and cartilage volume loss in a population with clinical knee osteoarthritis. Arthritis Rheum. 2011;63:700-7. doi: 10.1002/art.30182

35. Shiau MY, Tsai ST, Tsai KJ, et al. Increased circulatory MMP-2 and MMP-9 levels and activities in patients with type 1 diabetes mellitus. Mt Sinai J Med. 2006;73:1024-8.

36. Derosa G, D’Angelo A, Tinelli C, et al. Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in diabetic and healthy subjects. Diabetes Metab. 2007;33:129-34. doi: 10.1016/j.diabet.2006.11.008

37. Maxwell PR, Timms PM, Chandran S, Gordon D. Peripheral bloodlevel alterations of TIMP-1, MMP-2 and MMP-9 in patients with type 1 diabetes. Diabet Med. 2001;18:777-80. doi: 10.1046/j.1464-5491.2001.00542.x

38. Florys B, Glowinska B, Urban M, Peczynska J. Metalloproteinases MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 levels in children and adolescents with type 1 diabetes. Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw. 2006;12:184-9.

39. Shah AK, Clatworthy MR, Watson CJ. Diabetic cheiroarthropathy following simultaneous pancreas-kidney transplantation. Transplant Int. 2009;22:670-1. doi: 10.1111/j.1432-2277.2008.00825.x

40. Паневин ТС, Алекперов РТ, Мельниченко ГА. Синдром Рейно в практике эндокринолога. Ожирение и метаболизм. 2019;16(4):37-45. doi: 10.14341/omet10245 [Panevin TS, Alekperov RT, Melnichenko GA. Raynaud’s phenomenon in the endocrinologist’s practice. Ozhirenie i Metabolizm = Obesity and Metabolism. 2019;16(4):37-45. doi: 10.14341/omet10245 (In Russ.)].

41. Sauseng S, Kä stenbauer T, Irsigler K. Limited joint mobility in selected hand and foot joints in patients with type 1 diabetes mellitus: a methodology comparison. Diabetes Nutr Metab. 2002;15:1-6.

42. Lopez-Martin I, Benito Ortiz L, Rodriguez-Borlado B, et al. Association between limited joint mobility syndrome and risk of accidental falls in diabetic patients. Semergen. 2015;41:70-7. doi: 10.1016/j.semerg.2014.03.007

43. Kidd R, Kidd R. The role of abnormal collagen synthesis in the pathomechanics of the diabetic foot: a reevaluation of the paradism of neuropathy in podiatric practice. Aust Pod. 1993;(Dec):97-101.

44. Delbridge L, Perry P, Marr S, et al. Limited joint mobility in the diabetic foot: relationship to neuropathic ulceration. Diabet Med. 1988;5:333-7. doi: 10.1111/j.1464-5491.1988.tb01000.x

45. Fernando DJ, Masson EA, Veves A, Boulton AJ. Relationship of limited joint mobility to abnormal foot pressures and diabetic foot ulceration. Diabetes Care. 1991;14:8-11. doi: 10.2337/diacare.14.1.8

46. Ismail AA, Dasgupta B, Tanqueray AB, Hamblin JJ. Ultrasonographic features of diabetic cheiroarthropathy. Br J Rheumatol. 1996;35:676-9. doi: 10.1093/rheumatology/35.7.676

47. Кондратьева ЛВ, Попкова ТВ. Ревматические проявления сахарного диабета. Научно-практическая ревматология. 2018;56(5):603-12. doi: 10.14412/1995-4484-2018-603-612 [Kondratyeva LV, Popkova TV. Rheumatic manifestations of diabetes mellitus. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(5):603-12. doi: 10.14412/1995-4484-2018-603-612 (In Russ.)].

48. Паневин ТС, Молашенко НВ, Трошина ЕА, Головенко ЕН. Аутоиммунный полигландулярный синдром взрослых: современные представления о предикторах развития поражения миокарда и диагностике компонентов заболевания. Клиническая и экспериментальная тиреоидология. 2018;14(2):92-9. doi: 10.14341/ket9641 [Panevin TS, Molashenko NV, Troshina EA, Golovenko EN. Autoimmune polyglandular syndrome of adults: current ideas about predictors development of damage of a myocardium and diagnostics of components of a disease. Klinicheskaya i Eksperimental'naya Tireoidologiya = Clinical and Experimental Thyroidology. 2018;14(2):92-9. doi: 10.14341/ket9641 (In Russ.)].

49. Ramchurn N, Mashamba C, Leitch E, et al. Upper limb musculoskeletal abnormalities and poor metabolic control in diabetes. Eur J Intern Med. 2009;20:718-21. doi: 10.1016/j.ejim.2009.08.001

50. Francia P, Gulisano M, Anichini R, Seghieri G. Diabetic foot and exercise therapy: step by step the role of rigid posture and biomechanics treatment. Curr Diabetes Rev. 2014;10:86-99. doi: 10.2174/1573399810666140507112536

51. Lawall H, Diehm C. Diabetic foot syndrome from the perspective of angiology and diabetology. Orthopade. 2009;38:1149-15. doi: 10.1007/s00132-009-1501-z

52. Kim JB, Song BW, Park S, et al. Alagebrium chloride, a novel advanced glycation endproduct cross linkage breaker, inhibits neointimal proliferation in a diabetic rat carotid balloon injury model. Korean Circ J. 2010;40:520-6. doi: 10.4070/kcj.2010.40.10.520

53. Engelen L, Stehouwer CD, Schalkwijk CG. Current therapeutic interventions in the glycation pathway: evidence from clinical studies. Diabetes Obes Metab. 2013;15:677-89. doi: 10.1111/dom.12058

54. Katakami N, Matsuhisa M, Kaneto H, et al. Serum endogenous secretory RAGE level is an independent risk factor for the progression of carotid atherosclerosis in type 1 diabetes. Atherosclerosis. 2009;204:288-92. doi: 10.1016/j.atherosclerosis.2008.08.026

55. Hudson BI, Bucciarelli LG, Wendt T, et al. Blockade of receptor for advanced glycation endproducts: a new target for therapeutic intervention in diabetic complications and inflammatory disorders. Arch Biochem Biophys. 2003;419:80-8. doi: 10.1016/j.abb.2003.08.030